LivaNova FDA premarket approval for sleep apnea treatment
LivaNova announces it has received FDA premarket approval for its aura6000 neurostimulation system to treat moderate to severe obstructive sleep apnea, paving the way for U.S. commercialization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.